Serious adverse events to be reported, not poor trial performance during the trial.
Silence can be a good, especially in a fully recruited cancer trial where the measure is OS and results are delayed. Not the case in the BCBM trial it seems.
I am more interested in the Kazia sponsored GBM trial, because there is evidence of both efficacy and safety, and the results are overdue (see comment above), and if the final results are good the game is on proper. That seems to be the shortest pathway to a catalyst atm.
GLTA.
KZA Price at posting:
$1.31 Sentiment: Buy Disclosure: Held
